No relationship between socioeconomic status, education level and development and progression of diabetic retinopathy in type 2 diabetes: a FIELD trial substudy.


Journal

Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 13 05 2023
accepted: 16 09 2023
medline: 27 11 2023
pubmed: 24 11 2023
entrez: 24 11 2023
Statut: ppublish

Résumé

In 6002 Australian adults with type 2 diabetes and a median 5-year follow-up in the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) trial, baseline socioeconomic status (SES) and self-reported education level were not related to development of on-trial sight-threatening diabetic retinopathy. Similarly, in a retinal photography substudy (n = 549), two-step diabetic retinopathy progression was not related to SES or education.

Identifiants

pubmed: 37997276
doi: 10.1111/imj.16270
doi:

Substances chimiques

Fenofibrate U202363UOS

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2128-2131

Subventions

Organisme : National Health and Medical Research Council, Program Grant
ID : 1150467

Informations de copyright

© 2023 Royal Australasian College of Physicians.

Références

Tapp RJ, Shaw JE, Harper CA, de Courten MP, Balkau B, McCarty DJ et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care 2003; 26: 1731-1737.
Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012; 35: 556-564.
Low L, Law JP, Hodson J, McAlpine R, O'Colmain U, MacEwen C. Impact of socioeconomic deprivation on the development of diabetic retinopathy: a population-based, cross-sectional and longitudinal study over 12 years. BMJ Open 2015; 5: e007290.
Scanlon PH, Carter SC, Foy C, Husband RF, Abbas J, Bachmann MO. Diabetic retinopathy and socioeconomic deprivation in Gloucestershire. J Med Screen 2008; 15: 118-121.
Emoto N, Okajima F, Sugihara H, Goto R. A socioeconomic and behavioral survey of patients with difficult-to-control type 2 diabetes mellitus reveals an association between diabetic retinopathy and educational attainment. Patient Prefer Adherence 2016; 10: 2151-2162.
Foreman J, Keel S, van Wijngaarden P, Crowston J, Taylor HR. The National Eye Health Survey 2016. Melbourne: Centre for Eye Research Australia and Vision 2000 Australia; 2016.
Health Across Socioeconomic Groups. Australian Institute of Health and Welfare; 2022.
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.
Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687-1697.
Census of Population and Housing: Socio-Economic Indexes for Areas: Australian Bureau of Statistics; 2011. Available from URL: https://www.abs.gov.au/websitedbs/censushome.nsf/home/seifapast?opendocument&navpos=260
Klein R, Klein BE, Jensen SC, Moss SE. The relation of socioeconomic factors to the incidence of proliferative diabetic retinopathy and loss of vision. Ophthalmology 1994; 101: 68-76.
Dunstan DW, Zimmet PZ, Welborn TA, Cameron AJ, Shaw J, de Courten M et al. The Australian diabetes, obesity and lifestyle study (AusDiab) - methods and response rates. Diabetes Res Clin Pract 2002; 57: 119-129.
Lascar N, Brown J, Pattison H, Barnett AH, Bailey CJ, Bellary S. Type 2 diabetes in adolescents and young adults. Lancet Diabetes Endocrinol 2018; 6: 69-80.
Rodriguez-Poncelas A, Mundet-Tuduri X, Miravet-Jimenez S, Casellas A, Barrot-De la Puente JF, Franch-Nadal J et al. Chronic kidney disease and diabetic retinopathy in patients with type 2 diabetes. PLoS One 2016; 11: e0149448.
van Hecke MV, Dekker JM, Stehouwer CD, Polak BC, Fuller JH, Sjolie AK et al. Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: the EURODIAB prospective complications study. Diabetes Care 2005; 28: 1383-1389.
National Health and Medical Research Council. Clinical Guidelines for the Management of Diabetic Retinopathy. Canberra, ACT, Australia; 2008.
Chew EY, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology 2014; 121: 2443-2451.
Australian Public Assessment Report for fenofibrate: Therapeutic Goods Administration; 2014. Available from URL: https://www.tga.gov.au/sites/default/files/auspar-fenofibrate-141208.pdf
Wong TY, Sun J, Kawasaki R, Ruamviboonsuk P, Gupta N, Lansingh VC et al. Guidelines on diabetic eye care: the International Council of Ophthalmology Recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology 2018; 125: 1608-1622.
The Royal Australian College of General Practitioners. Management of Type 2 Diabetes: A Handbook for General Practice. East Melbourne, VIC: The Royal Australian College of General Practitioners; 2020.

Auteurs

Ben Rao (B)

NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.
Faculty of Medicine, Monash University, Melbourne, Victoria, Australia.

Andrzej S Januszewski (AS)

NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.
Sydney Pharmacy School, The University of Sydney, Sydney, New South Wales, Australia.
Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.

Laima Brazionis (L)

Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.

Rachel O'Connell (R)

NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.

Nanda Aryal (N)

Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia.

Georgia Shimmin (G)

NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.

Justin O'Day (J)

Department of Ophthalmology, Royal Victorian Eye and Ear Hospital, The University of Melbourne, Melbourne, Victoria, Australia.

Paul Mitchell (P)

The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.

Peter G Colman (PG)

Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.
Royal Melbourne Hospital, Melbourne, Victoria, Australia.

Anthony C Keech (AC)

NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.

Alicia J Jenkins (AJ)

NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.
Faculty of Medicine, Monash University, Melbourne, Victoria, Australia.
Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH